PPD Box containing Blood-taking Items for Phase 3 Novavax 2019nCoV-302 Vaccine Trial

PPD box containing blood-taking items from kit for phase 3 Novavax 2019nCoV-302 vaccine trial at Stockport NHS Foundation Trust.

Launched in September 2020, the phase 3 trial of Novavax’s vaccine was the largest ever double blind placebo controlled trial to be undertaken in the United Kingdom. This meant that the researchers or participants did not know what injection people received. Half of the participants were given the active vaccine and the other half, an inactive solution.15,000 people were involved from 35 research sites. The highest recruiting region was Greater Manchester with 1240 volunteers from Stockport NHS Foundation Trust and the Northern Care Alliance NHS Group. This kit was used with volunteers to monitor them during the trial and represents the crucial role volunteers play in the process.

Phase 3 trial results showed an overall 89.7% efficacy rate including against alpha and beta variants of the virus. Earlier clinical trials were carried out in Australia, United States and South Africa. All volunteers who received placebo solution are to be offered the active vaccine.

Details

Category:
Public Health & Hygiene
Object Number:
2022-1441/4
Materials:
plastic (unidentified), cardboard and paper (fibre product)
type:
test kit (medical)
credit:
Novavax, Inc

Parts

PPD Box for Phase 3 Novavax 2019nCoV-302 Vaccine Trial

PPD Box for Phase 3 Novavax 2019nCoV-302 Vaccine Trial

PPD box for kit for phase 3 Novavax 2019nCoV-302 vaccine trial at Stockport NHS Foundation Trust.

More

Launched in September 2020, the phase 3 trial of Novavax’s vaccine was the largest ever double blind placebo controlled trial to be undertaken in the United Kingdom. This meant that the researchers or participants did not know what injection people received. Half of the participants were given the active vaccine and the other half, an inactive solution.15,000 people were involved from 35 research sites. The highest recruiting region was Greater Manchester with 1240 volunteers from Stockport NHS Foundation Trust and the Northern Care Alliance NHS Group. This kit was used with volunteers to monitor them during the trial and represents the crucial role volunteers play in the process.

Phase 3 trial results showed an overall 89.7% efficacy rate including against alpha and beta variants of the virus. Earlier clinical trials were carried out in Australia, United States and South Africa. All volunteers who received placebo solution are to be offered the active vaccine.

Materials:
cardboard
Object Number:
2022-1441/4/1
type:
box - container
Digital Thermometer in Box for Phase 3 Novavax 2019nCoV-302 Vaccine Trial

Digital Thermometer in Box for Phase 3 Novavax 2019nCoV-302 Vaccine Trial

Digital thermometer in box model HK-901 made by Dong Guan City Good Health Electronic Technology Co Ltd., from kit for phase 3 Novavax 2019nCoV-302 vaccine trial at Stockport NHS Foundation Trust.

More

Launched in September 2020, the phase 3 trial of Novavax’s vaccine was the largest ever double blind placebo controlled trial to be undertaken in the United Kingdom. This meant that the researchers or participants did not know what injection people received. Half of the participants were given the active vaccine and the other half, an inactive solution.15,000 people were involved from 35 research sites. The highest recruiting region was Greater Manchester with 1240 volunteers from Stockport NHS Foundation Trust and the Northern Care Alliance NHS Group. This kit was used with volunteers to monitor them during the trial and represents the crucial role volunteers play in the process.

Phase 3 trial results showed an overall 89.7% efficacy rate including against alpha and beta variants of the virus. Earlier clinical trials were carried out in Australia, United States and South Africa. All volunteers who received placebo solution are to be offered the active vaccine.

Materials:
cardboard and plastic (unidentified)
Object Number:
2022-1441/4/2
type:
thermometer and box - container
Digital Thermometer for Phase 3 Novavax 2019nCoV-302 Vaccine Trial

Digital Thermometer for Phase 3 Novavax 2019nCoV-302 Vaccine Trial

Digital thermometer model HK-901 made by Dong Guan City Good Health Electronic Technology Co Ltd., from kit for phase 3 Novavax 2019nCoV-302 vaccine trial at Stockport NHS Foundation Trust.

More

Launched in September 2020, the phase 3 trial of Novavax’s vaccine was the largest ever double blind placebo controlled trial to be undertaken in the United Kingdom. This meant that the researchers or participants did not know what injection people received. Half of the participants were given the active vaccine and the other half, an inactive solution.15,000 people were involved from 35 research sites. The highest recruiting region was Greater Manchester with 1240 volunteers from Stockport NHS Foundation Trust and the Northern Care Alliance NHS Group. This kit was used with volunteers to monitor them during the trial and represents the crucial role volunteers play in the process.

Phase 3 trial results showed an overall 89.7% efficacy rate including against alpha and beta variants of the virus. Earlier clinical trials were carried out in Australia, United States and South Africa. All volunteers who received placebo solution are to be offered the active vaccine.

Materials:
plastic (unidentified)
Object Number:
2022-1441/4/2/1
type:
thermometer
Part of:
2022-1441/4/2
Box for Digital Thermometer for Phase 3 Novavax 2019nCoV-302 Vaccine Trial

Box for Digital Thermometer for Phase 3 Novavax 2019nCoV-302 Vaccine Trial

Box for digital thermometer model HK-901 made by Dong Guan City Good Health Electronic Technology Co Ltd., from kit for phase 3 Novavax 2019nCoV-302 vaccine trial at Stockport NHS Foundation Trust.

More

Launched in September 2020, the phase 3 trial of Novavax’s vaccine was the largest ever double blind placebo controlled trial to be undertaken in the United Kingdom. This meant that the researchers or participants did not know what injection people received. Half of the participants were given the active vaccine and the other half, an inactive solution.15,000 people were involved from 35 research sites. The highest recruiting region was Greater Manchester with 1240 volunteers from Stockport NHS Foundation Trust and the Northern Care Alliance NHS Group. This kit was used with volunteers to monitor them during the trial and represents the crucial role volunteers play in the process.

Phase 3 trial results showed an overall 89.7% efficacy rate including against alpha and beta variants of the virus. Earlier clinical trials were carried out in Australia, United States and South Africa. All volunteers who received placebo solution are to be offered the active vaccine.

Measurements:
overall: 21 mm x 137 mm x 21 mm,
Materials:
cardboard
Object Number:
2022-1441/4/2/2
type:
box - container
Part of:
2022-1441/4/2
Blank Study Identification Card for Phase 3 Novavax 2019nCoV-302 Vaccine Trial

Blank Study Identification Card for Phase 3 Novavax 2019nCoV-302 Vaccine Trial

Blank Study Identification Card version 1.0: 7 September 2020, from kit for phase 3 Novavax 2019nCoV-302 vaccine trial at Stockport NHS Foundation Trust.

More

Launched in September 2020, the phase 3 trial of Novavax’s vaccine was the largest ever double blind placebo controlled trial to be undertaken in the United Kingdom. This meant that the researchers or participants did not know what injection people received. Half of the participants were given the active vaccine and the other half, an inactive solution.15,000 people were involved from 35 research sites. The highest recruiting region was Greater Manchester with 1240 volunteers from Stockport NHS Foundation Trust and the Northern Care Alliance NHS Group. This kit was used with volunteers to monitor them during the trial and represents the crucial role volunteers play in the process.

Phase 3 trial results showed an overall 89.7% efficacy rate including against alpha and beta variants of the virus. Earlier clinical trials were carried out in Australia, United States and South Africa. All volunteers who received placebo solution are to be offered the active vaccine.

Measurements:
overall: 81 mm x 112 mm
Materials:
paper (fibre product)
Object Number:
2022-1441/4/3
type:
identity card
“Do Not Mix Kits” Warning Notice for phase 3 Novavax 2019nCoV-302 vaccine trial

“Do Not Mix Kits” Warning Notice for phase 3 Novavax 2019nCoV-302 vaccine trial

Warning Notice “Do Not Mix Kits” card from kit for phase 3 Novavax 2019nCoV-302 vaccine trial at Stockport NHS Foundation Trust.

More

Launched in September 2020, the phase 3 trial of Novavax’s vaccine was the largest ever double blind placebo controlled trial to be undertaken in the United Kingdom. This meant that the researchers or participants did not know what injection people received. Half of the participants were given the active vaccine and the other half, an inactive solution.15,000 people were involved from 35 research sites. The highest recruiting region was Greater Manchester with 1240 volunteers from Stockport NHS Foundation Trust and the Northern Care Alliance NHS Group. This kit was used with volunteers to monitor them during the trial and represents the crucial role volunteers play in the process.

Phase 3 trial results showed an overall 89.7% efficacy rate including against alpha and beta variants of the virus. Earlier clinical trials were carried out in Australia, United States and South Africa. All volunteers who received placebo solution are to be offered the active vaccine.

Materials:
paper (fibre product)
Object Number:
2022-1441/4/4
type:
notice
PPD Sticker for Phase 3 Novavax 2019nCoV-302 Vaccine Trial

PPD Sticker for Phase 3 Novavax 2019nCoV-302 Vaccine Trial

Circular PPD sticker from kit for phase 3 Novavax 2019nCoV-302 vaccine trial at Stockport NHS Foundation Trust.

More

Launched in September 2020, the phase 3 trial of Novavax’s vaccine was the largest ever double blind placebo controlled trial to be undertaken in the United Kingdom. This meant that the researchers or participants did not know what injection people received. Half of the participants were given the active vaccine and the other half, an inactive solution.15,000 people were involved from 35 research sites. The highest recruiting region was Greater Manchester with 1240 volunteers from Stockport NHS Foundation Trust and the Northern Care Alliance NHS Group. This kit was used with volunteers to monitor them during the trial and represents the crucial role volunteers play in the process.

Phase 3 trial results showed an overall 89.7% efficacy rate including against alpha and beta variants of the virus. Earlier clinical trials were carried out in Australia, United States and South Africa. All volunteers who received placebo solution are to be offered the active vaccine.

Materials:
plastic (unidentified)
Object Number:
2022-1441/4/5
type:
sticker
Blood Collection Kit for Phase 3 Novavax 2019nCoV-302 Vaccine Trial

Blood Collection Kit for Phase 3 Novavax 2019nCoV-302 Vaccine Trial

Sealed polythene bag containing blood collection kit, consisting of one BD Vacutainer Eclipse™ blood collection needle reference 368350 made by Becton, Dickinson and Company; one empty tube with a clear cap labelled N-Protein 1 barcode 1JP29475946; one empty tube with a red screw-cap labelled N-Protein 2 barcode 1JP25544552; and one empty tube with red push cap labelled N-Protein Coll barcode 1JP25282506; all from kit for phase 3 Novavax 2019nCoV-302 vaccine trial at Stockport NHS Foundation Trust.

More

Launched in September 2020, the phase 3 trial of Novavax’s vaccine was the largest ever double blind placebo controlled trial to be undertaken in the United Kingdom. This meant that the researchers or participants did not know what injection people received. Half of the participants were given the active vaccine and the other half, an inactive solution.15,000 people were involved from 35 research sites. The highest recruiting region was Greater Manchester with 1240 volunteers from Stockport NHS Foundation Trust and the Northern Care Alliance NHS Group. This kit was used with volunteers to monitor them during the trial and represents the crucial role volunteers play in the process.

Phase 3 trial results showed an overall 89.7% efficacy rate including against alpha and beta variants of the virus. Earlier clinical trials were carried out in Australia, United States and South Africa. All volunteers who received placebo solution are to be offered the active vaccine.

Blood Collection Needle for Phase 3 Novavax 2019nCoV-302 Vaccine Trial

Blood Collection Needle for Phase 3 Novavax 2019nCoV-302 Vaccine Trial

BD Vacutainer Eclipse™ blood collection needle in sealed packet, reference 368350 made by Becton, Dickinson and Company. From blood collection kit for phase 3 Novavax 2019nCoV-302 vaccine trial at Stockport NHS Foundation Trust.

More

Launched in September 2020, the phase 3 trial of Novavax’s vaccine was the largest ever double blind placebo controlled trial to be undertaken in the United Kingdom. This meant that the researchers or participants did not know what injection people received. Half of the participants were given the active vaccine and the other half, an inactive solution.15,000 people were involved from 35 research sites. The highest recruiting region was Greater Manchester with 1240 volunteers from Stockport NHS Foundation Trust and the Northern Care Alliance NHS Group. This kit was used with volunteers to monitor them during the trial and represents the crucial role volunteers play in the process.

Phase 3 trial results showed an overall 89.7% efficacy rate including against alpha and beta variants of the virus. Earlier clinical trials were carried out in Australia, United States and South Africa. All volunteers who received placebo solution are to be offered the active vaccine.

Materials:
plastic (unidentified) and metal (unknown)
Object Number:
2022-1441/4/6/1
type:
needle - piercing tool
Part of:
2022-1441/4/6
Tube for Blood Collection Kit for Phase 3 Novavax 2019nCoV-302 Vaccine Trial

Tube for Blood Collection Kit for Phase 3 Novavax 2019nCoV-302 Vaccine Trial

Empty tube with a clear cap labelled N-Protein 1 barcode 1JP29475946, from blood collection kit for phase 3 Novavax 2019nCoV-302 vaccine trial at Stockport NHS Foundation Trust.

More

Launched in September 2020, the phase 3 trial of Novavax’s vaccine was the largest ever double blind placebo controlled trial to be undertaken in the United Kingdom. This meant that the researchers or participants did not know what injection people received. Half of the participants were given the active vaccine and the other half, an inactive solution.15,000 people were involved from 35 research sites. The highest recruiting region was Greater Manchester with 1240 volunteers from Stockport NHS Foundation Trust and the Northern Care Alliance NHS Group. This kit was used with volunteers to monitor them during the trial and represents the crucial role volunteers play in the process.

Phase 3 trial results showed an overall 89.7% efficacy rate including against alpha and beta variants of the virus. Earlier clinical trials were carried out in Australia, United States and South Africa. All volunteers who received placebo solution are to be offered the active vaccine.

Measurements:
overall: 98 mm 18 mm,
Materials:
plastic (unidentified) and paper (fibre product)
Object Number:
2022-1441/4/6/2
type:
container - receptacle
Part of:
2022-1441/4/6
Tube for Blood Collection Kit for Phase 3 Novavax 2019nCoV-302 Vaccine Trial

Tube for Blood Collection Kit for Phase 3 Novavax 2019nCoV-302 Vaccine Trial

Empty tube with a red screw-cap labelled N-Protein 2 barcode 1JP25544552, from blood collection kit for phase 3 Novavax 2019nCoV-302 vaccine trial at Stockport NHS Foundation Trust.

More

Launched in September 2020, the phase 3 trial of Novavax’s vaccine was the largest ever double blind placebo controlled trial to be undertaken in the United Kingdom. This meant that the researchers or participants did not know what injection people received. Half of the participants were given the active vaccine and the other half, an inactive solution.15,000 people were involved from 35 research sites. The highest recruiting region was Greater Manchester with 1240 volunteers from Stockport NHS Foundation Trust and the Northern Care Alliance NHS Group. This kit was used with volunteers to monitor them during the trial and represents the crucial role volunteers play in the process.

Phase 3 trial results showed an overall 89.7% efficacy rate including against alpha and beta variants of the virus. Earlier clinical trials were carried out in Australia, United States and South Africa. All volunteers who received placebo solution are to be offered the active vaccine.

Measurements:
overall: 50 mm 18 mm,
Materials:
plastic (unidentified) and paper (fibre product)
Object Number:
2022-1441/4/6/3
type:
container - receptacle
Part of:
2022-1441/4/6
Tube for Blood Collection Kit for Phase 3 Novavax 2019nCoV-302 Vaccine Trial

Tube for Blood Collection Kit for Phase 3 Novavax 2019nCoV-302 Vaccine Trial

Empty tube with red push cap labelled N-Protein Coll barcode 1JP25282506, from blood collection kit for phase 3 Novavax 2019nCoV-302 vaccine trial at Stockport NHS Foundation Trust.

More

Launched in September 2020, the phase 3 trial of Novavax’s vaccine was the largest ever double blind placebo controlled trial to be undertaken in the United Kingdom. This meant that the researchers or participants did not know what injection people received. Half of the participants were given the active vaccine and the other half, an inactive solution.15,000 people were involved from 35 research sites. The highest recruiting region was Greater Manchester with 1240 volunteers from Stockport NHS Foundation Trust and the Northern Care Alliance NHS Group. This kit was used with volunteers to monitor them during the trial and represents the crucial role volunteers play in the process.

Phase 3 trial results showed an overall 89.7% efficacy rate including against alpha and beta variants of the virus. Earlier clinical trials were carried out in Australia, United States and South Africa. All volunteers who received placebo solution are to be offered the active vaccine.

Measurements:
overall: 83 mm 11 mm,
Materials:
plastic (unidentified) and paper (fibre product)
Object Number:
2022-1441/4/6/4
type:
container - receptacle
Part of:
2022-1441/4/6
Pipette for Blood Collection Kit for Phase 3 Novavax 2019nCoV-302 Vaccine Trial

Pipette for Blood Collection Kit for Phase 3 Novavax 2019nCoV-302 Vaccine Trial

Pipette from blood collection kit for phase 3 Novavax 2019nCoV-302 vaccine trial at Stockport NHS Foundation Trust.

More

Launched in September 2020, the phase 3 trial of Novavax’s vaccine was the largest ever double blind placebo controlled trial to be undertaken in the United Kingdom. This meant that the researchers or participants did not know what injection people received. Half of the participants were given the active vaccine and the other half, an inactive solution.15,000 people were involved from 35 research sites. The highest recruiting region was Greater Manchester with 1240 volunteers from Stockport NHS Foundation Trust and the Northern Care Alliance NHS Group. This kit was used with volunteers to monitor them during the trial and represents the crucial role volunteers play in the process.

Phase 3 trial results showed an overall 89.7% efficacy rate including against alpha and beta variants of the virus. Earlier clinical trials were carried out in Australia, United States and South Africa. All volunteers who received placebo solution are to be offered the active vaccine.

Materials:
plastic (unidentified)
Object Number:
2022-1441/4/6/5
type:
pipette
Part of:
2022-1441/4/6
Bag for Blood Collection Kit for Phase 3 Novavax 2019nCoV-302 Vaccine Trial

Bag for Blood Collection Kit for Phase 3 Novavax 2019nCoV-302 Vaccine Trial

Polythene bag for blood collection kit for phase 3 Novavax 2019nCoV-302 vaccine trial at Stockport NHS Foundation Trust.

More

Launched in September 2020, the phase 3 trial of Novavax’s vaccine was the largest ever double blind placebo controlled trial to be undertaken in the United Kingdom. This meant that the researchers or participants did not know what injection people received. Half of the participants were given the active vaccine and the other half, an inactive solution.15,000 people were involved from 35 research sites. The highest recruiting region was Greater Manchester with 1240 volunteers from Stockport NHS Foundation Trust and the Northern Care Alliance NHS Group. This kit was used with volunteers to monitor them during the trial and represents the crucial role volunteers play in the process.

Phase 3 trial results showed an overall 89.7% efficacy rate including against alpha and beta variants of the virus. Earlier clinical trials were carried out in Australia, United States and South Africa. All volunteers who received placebo solution are to be offered the active vaccine.

Materials:
plastic (unidentified)
Object Number:
2022-1441/4/6/6
type:
bag - container
Part of:
2022-1441/4/6
PPD Requisition Form for Phase 3 Novavax 2019nCoV-302 Vaccine Trial

PPD Requisition Form for Phase 3 Novavax 2019nCoV-302 Vaccine Trial

PPD Requisition Form 2020 from kit for phase 3 Novavax 2019nCoV-302 vaccine trial at Stockport NHS Foundation Trust.

More

Launched in September 2020, the phase 3 trial of Novavax’s vaccine was the largest ever double blind placebo controlled trial to be undertaken in the United Kingdom. This meant that the researchers or participants did not know what injection people received. Half of the participants were given the active vaccine and the other half, an inactive solution.15,000 people were involved from 35 research sites. The highest recruiting region was Greater Manchester with 1240 volunteers from Stockport NHS Foundation Trust and the Northern Care Alliance NHS Group. This kit was used with volunteers to monitor them during the trial and represents the crucial role volunteers play in the process.

Phase 3 trial results showed an overall 89.7% efficacy rate including against alpha and beta variants of the virus. Earlier clinical trials were carried out in Australia, United States and South Africa. All volunteers who received placebo solution are to be offered the active vaccine.

Measurements:
overall: 297 mm x 210 mm
Materials:
paper (fibre product)
Object Number:
2022-1441/4/7
type:
form - document